Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact of Disease Modifying Therapies (DMTs) and Associated Support Services on Patient Reported Experience Measures (PREMs) and Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients

NCT01601119 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.

NCT NCT01601119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01601119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact of Disease Modifying Therapies (DMTs) and Associated Support Services on Patient Reported Experience Measures (PREMs) and Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Lead sponsor
Merck KGaA, Darmstadt, Germany
Phase
Observational
Overall status
Completed
Start date
January 31, 2012
Completion date
July 31, 2014
Enrollment
545 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing multiple sclerosis